Summary

On November 1st, the United Kingdom (UK) published the Bletchley Declaration on the opening day of the Artificial Intelligence (AI) Safety Summit hosted at Bletchley Park, central England.This declaration, made by the UK and joined by 28 countries and international organizations, aims to promote cooperation among them regarding AI.

Why Bletchley ? It was at Bletchley Park that the Enigma code was successfully deciphered during WW2 …

International efforts are being made to examine and address the potential impact of AI systems, especially on principles such as the protection of human rights, data protection, and ethics.👉🏻 The primary focus of this declaration is on Frontier AI. These AI are defined as highly capable general-purpose AI models and specific narrow AI that could exhibit capabilities causing harm

The core concerns of the organizations revolve around the risks posed by Frontier AI, particularly in the domains of cybersecurity and biotechnology. Through international cooperation, they aim to deepen their understanding of these risks and identify actions to address them.

A regulatory approach will be considered by the participating organizations. This includes making, where appropriate, classifications and categorizations of risk based on national circumstances and applicable legal frameworks. International codes of conduct may result from this cooperation.

All AI actors are affected by this Declaration. Actors who develop Frontier AI have a significant responsibility to ensure the safety of these systems. The organizations encourage these actors to provide context-appropriate transparency and accountability in their plans to measure, monitor, and mitigate potentially harmful capabilities and associated effects, particularly to prevent misuse and issues of control, as well as the amplification of other risks.

Click here to read more

Seamus Larroque

CDPO / CPIM / ISO 27005 Certified

Home

Discover our latest articles

View All Blog Posts
July 16, 2025
Clinical Trial Sponsor
Clinical Trials

Data Protection Strategies for Phase III Clinical Trials

Phase III clinical trials require strict compliance with privacy and data protection laws across multiple jurisdictions, including GDPR obligations, local authorizations, and ethics committee oversight. The article outlines practical strategies such as the “funnel approach” to harmonize global frameworks, manage cross-border transfers, appoint Data Protection Officers, and ensure proper informed consent documentation. It also emphasizes the need for local representatives, jurisdiction-specific formalities, and standardized templates to maintain compliance and avoid delays in global studies.

June 10, 2025
AI
USA
Biotech & Healthtech

Addressing the Data Protection and Ethical Challenges posed by AI in Health – Part 2

Our latest analysis: U.S. vs EU—AI regulation shaping healthcare’s future.